MyD88 and its divergent toll in carcinogenesis

Trends in Immunology

Volumn 34, Issue 8, 2013, Pages 379-389

  Salcedo, Rosalba ^a   Cataisson, Christophe ^b   Hasan, Uzma ^c   Yuspa, Stuart H ^b   Trinchieri, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

Cancer and inflammation; Colon carcinogenesis; Interleukin 1 family receptors; Oncogene induced inflammation; Skin carcinogenesis; Toll like receptors

Indexed keywords

AZOXYMETHANE; CYTOKINE; DEXTRAN SULFATE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 36; INTERLEUKIN 37; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

CARCINOGENESIS; COLON CARCINOGENESIS; HOMEOSTASIS; HUMAN; IMMUNITY; INFLAMMATION; KERATINOCYTE; LIVER CARCINOGENESIS; NONHUMAN; ONCOGENE; PANCREAS; REVIEW; SKIN CARCINOGENESIS; TISSUE REPAIR; TUMOR VIRUS;

CANCER AND INFLAMMATION; COLON CARCINOGENESIS; INTERLEUKIN-1 FAMILY RECEPTORS; ONCOGENE-INDUCED INFLAMMATION; SKIN CARCINOGENESIS; TOLL-LIKE RECEPTORS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MYELOID DIFFERENTIATION FACTOR 88;

EID: 84881026342     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2013.03.008     Document Type: Review

References (103)

1. Zitvogel L., et al. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006, 6:715-727.
2. Colotta F., et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 2012, 30:677-706.
5. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006, 118:3030-3044.
6. Goldszmid R.S., Trinchieri G. The price of immunity. Nat. Immunol. 2012, 13:932-938.
7. Jobin C. Colorectal cancer: CRC - all about microbial products and barrier function?. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:694-696.
8. Schetter A.J., et al. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010, 31:37-49.
9. Grivennikov S.I., et al. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
10. Takeda K., et al. Toll-like receptors. Annu. Rev. Immunol. 2003, 21:335-376.
11. Ngo V.N., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
12. Treon S.P., et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N. Engl. J. Med. 2012, 367:826-833.
13. Wang E.L., et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br. J. Cancer 2010, 102:908-915.
14. Je E.M., et al. Mutational and expressional analyses of MYD88 gene in common solid cancers. Tumori 2012, 98:663-669.
15. El-Omar E.M., et al. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 2008, 27:244-252.
16. Hold G.L., et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007, 132:905-912.
17. Roszak A., et al. Involvement of Toll-like Receptor 9 polymorphism in cervical cancer development. Mol. Biol. Rep. 2012, 39:8425-8430.
18. Stevens V.L., et al. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int. J. Cancer 2008, 123:2644-2650.
19. Engels E.A., et al. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res. 2007, 67:6520-6527.
20. Han W., et al. Multiplex genotyping of 1107 SNPs from 232 candidate genes identified an association between IL1A polymorphism and breast cancer risk. Oncol. Rep. 2010, 23:763-769.
21. Sugimoto M., et al. Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori. J. Gastroenterol. Hepatol. 2009, 24:1725-1732.
22. Jatoi A., et al. The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer. Support. Care Cancer 2010, 18:1299-1304.
23. DiDonato J.A., et al. NF-kappaB and the link between inflammation and cancer. Immunol. Rev. 2012, 246:379-400.
24. Saleh M., Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat. Rev. Immunol. 2011, 11:9-20.
25. Dinarello C.A. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J. Endotoxin Res. 2004, 10:201-222.
26. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat. Rev. Cancer 2009, 9:57-63.
27. Hasan U.A., et al. Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:8047-8052.
28. Hasan U.A., et al. Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts. J. Biol. Chem. 2005, 280:20620-20627.
29. Salaun B., et al. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 2006, 176:4894-4901.
30. Salaun B., et al. Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur. J. Immunol. 2007, 37:3311-3318.
31. Monick M.M., et al. Lipopolysaccharide activates Akt in human alveolar macrophages resulting in nuclear accumulation and transcriptional activity of beta-catenin. J. Immunol. 2001, 166:4713-4720.
32. Macedo L., et al. Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am. J. Pathol. 2007, 171:1774-1788.
33. Rakoff-Nahoum S., et al. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229.
34. Iimuro Y., et al. Role of innate immune response in liver regeneration. J. Gastroenterol. Hepatol. 2007, 22(Suppl. 1):S57-S58.
35. Chong H.C., et al. Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing. J. Cell Biol. 2009, 184:817-831.
36. Barton C.E., et al. Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation. Cell Death Dis. 2010, 1:e74.
37. Salcedo R., et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. 2010, 207:1625-1636.
38. Naik S., et al. Compartmentalized control of skin immunity by resident commensals. Science 2012, 337:1115-1119.
39. Swann J.B., et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:652-656.
40. Mittal D., et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 2010, 29:2242-2252.
41. Coste I., et al. Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J. Clin. Invest. 2010, 120:3663-3667.
42. Cataisson C., et al. IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. J. Exp. Med. 2012, 209:1689-1702.
43. Darwiche N., et al. Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion. Oncogene 2007, 26:6885-6895.
44. Yusuf N., et al. Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res. 2008, 68:615-622.
45. Lee W.Y., et al. Interleukin-1 alpha mediates phorbol ester-induced inflammation and epidermal hyperplasia. FASEB J. 1994, 8:1081-1087.
46. Li X., et al. Interleukin-1alpha up-regulation in vivo by a potent carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) and control of DMBA-induced inflammatory responses. Cancer Res. 2002, 62:417-423.
47. Muller A.J., et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17073-17078.
48. Caunt C.J., et al. Ras controls tumor necrosis factor receptor-associated factor (TRAF)6-dependent induction of nuclear factor-kappa b. Selective regulation through receptor signaling components. J. Biol. Chem. 2001, 276:6280-6288.
49. McDermott E.P., O'Neill L.A. Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6, and TAK-1. J. Biol. Chem. 2002, 277:7808-7815.
50. Wang K.Z., et al. TRAF6 activation of PI 3-kinase-dependent cytoskeletal changes is cooperative with Ras and is mediated by an interaction with cytoplasmic Src. J. Cell Sci. 2006, 119:1579-1591.
51. Xu H., et al. Ras participates in CpG oligodeoxynucleotide signaling through association with toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor 6 complex formation in macrophages. J. Biol. Chem. 2003, 278:36334-36340.
52. Starczynowski D.T., et al. TRAF6 is an amplified oncogene bridging the RAS and NF-kappaB pathways in human lung cancer. J. Clin. Invest. 2011, 121:4095-4105.
53. Mueller M.M. Inflammation in epithelial skin tumours: old stories and new ideas. Eur. J. Cancer 2006, 42:735-744.
54. Cataisson C., et al. Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis. Cancer Res. 2009, 69:319-328.
55. Mahanivong C., et al. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 2008, 27:1273-1280.
56. Staudt L.M. Oncogenic activation of NF-kappaB. Cold Spring Harb. Perspect. Biol. 2010, 2:a000109.
57. Hobbs R.M., Watt F.M. Regulation of interleukin-1alpha expression by integrins and epidermal growth factor receptor in keratinocytes from a mouse model of inflammatory skin disease. J. Biol. Chem. 2003, 278:19798-19807.
58. Mascia F., et al. EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo. J. Invest. Dermatol. 2010, 130:682-693.
59. Streicher K.L., et al. Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells. Mol. Cancer Res. 2007, 5:847-861.
60. Cohen I., et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2574-2579.
61. Borrello M.G., et al. Inflammation and cancer: the oncogene-driven connection. Cancer Lett. 2008, 267:262-270.
62. Wang B., et al. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res. 2006, 66:3071-3077.
63. Shang K., et al. Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS ONE 2012, 7:e51848.
64. Acharyya S., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012, 150:165-178.
65. Jamieson T., et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J. Clin. Invest. 2012, 122:3127-3144.
66. Campisi J. Cellular senescence: putting the paradoxes in perspective. Curr. Opin. Genet. Dev. 2011, 21:107-112.
67. Rodier F., et al. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J. Cell Sci. 2011, 124:68-81.
68. Rodier F., et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 2009, 11:973-979.
69. Orjalo A.V., et al. Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17031-17036.
70. Sharpless N.E., DePinho R.A. Cancer: crime and punishment. Nature 2005, 436:636-637.
71. Halazonetis T.D., et al. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
72. Edme N., et al. Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. J. Cell Sci. 2002, 115:2591-2601.
73. Loercher A., et al. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res. 2004, 64:6511-6523.
74. Dajee M., et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003, 421:639-643.
75. Naugler W.E., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
76. Moore R.J., et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 1999, 5:828-831.
77. Schreiber R.D., et al. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
78. Wu J., et al. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res. 2012, 72:3977-3986.
79. Ling J., et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:105-120.
80. Ochi A., et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J. Exp. Med. 2012, 209:1671-1687.
81. Rakoff-Nahoum S., Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127.
82. Uronis J.M., et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS ONE 2009, 4:e6026.
83. Araki A., et al. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J. Gastroenterol. 2005, 40:16-23.
84. Brown S.L., et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J. Clin. Invest. 2007, 117:258-269.
85. Pull S.L., et al. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:99-104.
86. Greten F.R., et al. IKKb links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285.
87. Lowe E.L., et al. Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS ONE 2010, 5:e13027.
88. Fukata M., et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007, 133:1869-1881.
89. Allen I.C., et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 2010, 207:1045-1056.
90. Elinav E., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145:745-757.
91. Huber S., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012, 491:259-263.
92. Zenewicz L.A., et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008, 29:947-957.
93. Grivennikov S.I., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491:254-258.
94. Fathallah I., et al. EBV latent membrane protein 1 is a negative regulator of TLR9. J. Immunol. 2010, 185:6439-6447.
95. Vincent I.E., et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS ONE 2011, 6:e26315.
96. Hasan U.A., et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 2007, 178:3186-3197.
97. Young G.R., et al. Resurrection of endogenous retroviruses in antibody-deficient mice. Nature 2012, 491:774-778.
98. Yu P., et al. Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors. Immunity 2012, 37:867-879.
99. Kane M., et al. Successful transmission of a retrovirus depends on the commensal microbiota. Science 2011, 334:245-249.
100. Boraschi D., et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur. Cytokine Netw. 2011, 22:127-147.
101. Guo L., et al. Cytokine-induced cytokine production by conventional and innate lymphoid cells. Trends Immunol. 2012, 33:598-606.
102. Denning M.F., et al. Expression of an oncogenic rasHa gene in murine keratinocytes induces tyrosine phosphorylation and reduced activity of protein kinase C delta. J. Biol. Chem. 1993, 268:26079-26081.
103. Kalina U., et al. Enhanced production of IL-18 in butyrate-treated intestinal epithelium by stimulation of the proximal promoter region. Eur. J. Immunol. 2002, 32:2635-2643.